Schächtele C - Search Results

1

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R.

Hempel C, Totzke F, Schächtele C, Najjar A, Sippl W, Ritter C, Hilgeroth A. Hempel C, et al. Among authors: schachtele c. J Enzyme Inhib Med Chem. 2017 Dec;32(1):271-276. doi: 10.1080/14756366.2016.1247062. J Enzyme Inhib Med Chem. 2017. PMID: 28097905 Free PMC article.

2

Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.

Krug M, Erlenkamp G, Sippl W, Schächtele C, Totzke F, Hilgeroth A. Krug M, et al. Among authors: schachtele c. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6915-9. doi: 10.1016/j.bmcl.2010.10.004. Epub 2010 Oct 27. Bioorg Med Chem Lett. 2010. PMID: 21035334

3

Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.

Krug M, Wichapong K, Erlenkamp G, Sippl W, Schächtele C, Totzke F, Hilgeroth A. Krug M, et al. Among authors: schachtele c. ChemMedChem. 2011 Jan 3;6(1):63-72. doi: 10.1002/cmdc.201000384. ChemMedChem. 2011. PMID: 21140395

4

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.

Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ. Barbosa ML, et al. Among authors: schachtele c. Eur J Med Chem. 2014 Jan;71:1-14. doi: 10.1016/j.ejmech.2013.10.058. Epub 2013 Oct 31. Eur J Med Chem. 2014. PMID: 24269511

5

Discovery of 4-anilino α-carbolines as novel Brk inhibitors.

Mahmoud KA, Krug M, Wersig T, Slynko I, Schächtele C, Totzke F, Sippl W, Hilgeroth A. Mahmoud KA, et al. Among authors: schachtele c. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1948-51. doi: 10.1016/j.bmcl.2014.03.002. Epub 2014 Mar 12. Bioorg Med Chem Lett. 2014. PMID: 24650640

6

Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.

Fischer T, Krüger T, Najjar A, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A. Fischer T, et al. Among authors: schachtele c. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2708-2712. doi: 10.1016/j.bmcl.2017.04.053. Epub 2017 Apr 19. Bioorg Med Chem Lett. 2017. PMID: 28478927

7

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.

Fischer T, Najjar A, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A. Fischer T, et al. Among authors: schachtele c. J Enzyme Inhib Med Chem. 2018 Dec;33(1):1-8. doi: 10.1080/14756366.2017.1370583. J Enzyme Inhib Med Chem. 2018. PMID: 29098884 Free PMC article.

8

Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.

Voigt B, Krug M, Schächtele C, Totzke F, Hilgeroth A. Voigt B, et al. Among authors: schachtele c. ChemMedChem. 2008 Jan;3(1):120-6. doi: 10.1002/cmdc.200700175. ChemMedChem. 2008. PMID: 18000938

9

Dual IGF-1R/SRC inhibitors based on a N'-aroyl-2-(1H-indol-3-yl)-2-oxoacetohydrazide structure.

Schmidt S, Preu L, Lemcke T, Totzke F, Schächtele C, Kubbutat MH, Kunick C. Schmidt S, et al. Among authors: schachtele c. Eur J Med Chem. 2011 Jul;46(7):2759-69. doi: 10.1016/j.ejmech.2011.03.065. Epub 2011 Apr 6. Eur J Med Chem. 2011. PMID: 21524503

10

Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.

Beckers T, Sellmer A, Eichhorn E, Pongratz H, Schächtele C, Totzke F, Kelter G, Krumbach R, Fiebig HH, Böhmer FD, Mahboobi S. Beckers T, et al. Among authors: schachtele c. Bioorg Med Chem. 2012 Jan 1;20(1):125-36. doi: 10.1016/j.bmc.2011.11.023. Epub 2011 Nov 20. Bioorg Med Chem. 2012. PMID: 22169601

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page